关于“竖向折叠”的报告
-
艾媒咨询|2022年中国新经济行业趋势报告
2022 年 1 月 6日，由艾媒咨询主办的“艾媒之夜—2022年新经济趋势分析大会”在广州隆重举行。本次大会以“洞察风向、数读未来”为主题，分析复盘2021全年行业热门事件，洞察预测2022年新经济行业发展前景，让一部分人先看到先机，赢在未来。活动设置报告发布、主题演讲、圆桌论坛、奖项颁发等基本环节，现场隆重揭晓“2021新经济行业年度巅峰榜”获奖品牌，并授予荣誉证书。艾媒咨询CEO兼首席分析师张毅受邀出席本次活动，现场发布了《2022中国新经济产业趋势分析报告》，并结合艾媒长期的监测研究，用数据说话，从行业前景、人群洞察、投资布局三个角度对新经济行业展开详细的分析解读，直击品牌价值，共同展望未来新经济行业发展趋势。
On January 6, 2022, the "Ai media night - 2022 new economic trend analysis conference" hosted by AI media consulting was grandly held in Guangzhou. With the theme of "insight into the wind direction and reading the future", this conference analyzes the hot events in the industry in 2021 and forecasts the development prospect of the new economy industry in 2022, so that some people can see the first opportunity and win in the future. The event set up basic links such as report release, keynote speech, round table forum and award presentation. The award-winning brands of "2021 annual peak list of new economic industries" were grandly announced on the spot, and the honorary certificate was awarded. Zhang Yi, CEO and chief analyst of AI media consulting, was invited to attend the event and released the 2022 China new economy industry trend analysis report. In combination with AI media's long-term monitoring and research, he used data to analyze and interpret the new economy industry in detail from the perspectives of industry prospect, crowd insight and investment layout, and directly hit the brand value, Jointly look forward to the development trend of new economic industries in the future. -
艾媒报告 |2019年中国柔性显示产业研究与商业投资决策分析报告
本报告研究涉及企业/品牌包括:三星、iPhone、华为、小米、OPPO、京东方、深天马A、TCL集团、微信诺、华星光电、信利国际、和辉光电、柔宇科技、中能源、湖南群显、联得装备、同兴达、志云股份、国风塑业、新纶科技、时代新材、鼎龙股份、激智科技、晶华新材、万润股份、强力新材、东旭光电、莱宝高科、长信科技、ST康得新、中颖电子、士兰微、凯盛科技、康达新材、西部材料、传艺科技、金明精机、光莆股份、样子想你才、神宇股份、海顺新材、茂硕电源
政策支持和技术进步共同推动中国柔性显示产业快速发展。iiMedia Research(艾媒咨询)监测发现，2018年中国柔性显示游产业链各个环节相关企业营收均超亿元，相关上市公司中京东方A(000725.SZ)的网络关注度最高，隆华科技(300263.SZ)的网络口碑最好。但由于技术门槛高等相关因素影响，中国柔性显示产业上游发展基础薄弱，产业存在发展不成熟、技术欠缺和市场份额不足等问题。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
